Cyclacel Pharmaceuticals Stock Price History
| CYCC Stock | USD 2.12 0.05 2.30% |
Below is the normalized historical share price chart for Cyclacel Pharmaceuticals extending back to March 16, 2004. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Cyclacel Pharmaceuticals stands at 2.12, as last reported on the 6th of June, with the highest price reaching 2.19 and the lowest price hitting 2.05 during the day.
If you're considering investing in Cyclacel Stock, it is important to understand the factors that can impact its price. Cyclacel Pharmaceuticals appears to be abnormally volatile, given 3 months investment horizon. Cyclacel Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0256, which signifies that the company had a 0.0256% return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Cyclacel Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Cyclacel Pharmaceuticals' risk adjusted performance of 0.0237, and Mean Deviation of 7.34 to double-check if our risk estimates are consistent with your expectations.
At present, Cyclacel Pharmaceuticals' Sale Purchase Of Stock is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 3.31, whereas Total Stockholder Equity is forecasted to decline to about 576.6 K. . At present, Cyclacel Pharmaceuticals' Price To Book Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Fair Value is expected to grow to 3.93, whereas Price To Sales Ratio is forecasted to decline to 5.91. Cyclacel Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 5th of May 2004 | 200 Day MA 3.922 | 50 Day MA 2.0868 | Beta 0.546 |
Cyclacel |
Sharpe Ratio = 0.0256
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CYCC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.2 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.31 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Cyclacel Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclacel Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 3.8223 | Enterprise Value Ebitda 0.0402 | Price Sales 5.5241 | Shares Float 1.1 M | Wall Street Target Price 11 |
Cyclacel Pharmaceuticals Stock Price History Chart
There are several ways to analyze Cyclacel Stock price data. The simplest method is using a basic Cyclacel candlestick price chart, which shows Cyclacel Pharmaceuticals price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | May 14, 2024 | 2.84 |
| Lowest Price | April 29, 2024 | 1.36 |
Cyclacel Pharmaceuticals June 6, 2024 Stock Price Synopsis
Various analyses of Cyclacel Pharmaceuticals' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Cyclacel Stock. It can be used to describe the percentage change in the price of Cyclacel Pharmaceuticals from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Cyclacel Stock.| Cyclacel Pharmaceuticals Price Daily Balance Of Power | (0.36) | |
| Cyclacel Pharmaceuticals Accumulation Distribution | 5,182 | |
| Cyclacel Pharmaceuticals Price Action Indicator | (0.02) | |
| Cyclacel Pharmaceuticals Price Rate Of Daily Change | 0.98 |
Cyclacel Pharmaceuticals June 6, 2024 Stock Price Analysis
Cyclacel Stock Price History Data
The price series of Cyclacel Pharmaceuticals for the period between Fri, Mar 8, 2024 and Thu, Jun 6, 2024 has a statistical range of 1.48 with a coefficient of variation of 14.05. The prices are distributed with arithmetic mean of 2.17. The median price for the last 90 days is 2.14. The company had 1:15 stock split on 18th of December 2023. Cyclacel Pharmaceuticals issued dividends on 2020-04-15.| Open | High | Low | Close | Volume | ||
| 06/05/2024 | 2.17 | 2.19 | 2.05 | 2.12 | 81,055 | |
| 06/04/2024 | 2.12 | 2.38 | 2.00 | 2.17 | 177,179 | |
| 06/03/2024 | 2.54 | 2.57 | 2.10 | 2.12 | 694,808 | |
| 05/31/2024 | 2.03 | 3.08 | 1.99 | 2.64 | 2,352,802 | |
| 05/30/2024 | 2.02 | 2.05 | 1.99 | 2.02 | 20,967 | |
| 05/29/2024 | 2.00 | 2.07 | 1.96 | 2.05 | 44,025 | |
| 05/28/2024 | 2.11 | 2.15 | 1.93 | 2.01 | 53,366 | |
| 05/24/2024 | 2.05 | 2.12 | 1.99 | 2.05 | 41,682 | |
| 05/23/2024 | 2.13 | 2.13 | 2.01 | 2.05 | 60,079 | |
| 05/22/2024 | 2.24 | 2.24 | 2.11 | 2.12 | 30,043 | |
| 05/21/2024 | 2.18 | 2.33 | 2.11 | 2.25 | 45,644 | |
| 05/20/2024 | 2.37 | 2.37 | 2.14 | 2.18 | 82,307 | |
| 05/17/2024 | 2.28 | 2.40 | 2.23 | 2.29 | 34,988 | |
| 05/16/2024 | 2.39 | 2.48 | 2.25 | 2.34 | 51,615 | |
| 05/15/2024 | 2.81 | 2.81 | 2.30 | 2.44 | 164,959 | |
| 05/14/2024 | 2.22 | 2.84 | 2.22 | 2.84 | 260,187 | |
| 05/13/2024 | 2.46 | 2.72 | 2.37 | 2.54 | 381,758 | |
| 05/10/2024 | 2.22 | 2.30 | 2.16 | 2.27 | 82,157 | |
| 05/09/2024 | 2.35 | 2.60 | 2.27 | 2.31 | 204,740 | |
| 05/08/2024 | 2.13 | 2.50 | 2.06 | 2.32 | 326,502 | |
| 05/07/2024 | 2.07 | 2.18 | 2.02 | 2.11 | 248,148 | |
| 05/06/2024 | 1.94 | 2.20 | 1.93 | 2.07 | 262,544 | |
| 05/03/2024 | 2.37 | 2.52 | 1.94 | 2.00 | 565,955 | |
| 05/02/2024 | 2.50 | 3.15 | 2.44 | 2.49 | 1,808,090 | |
| 05/01/2024 | 1.90 | 4.00 | 1.89 | 2.65 | 17,561,299 | |
| 04/30/2024 | 1.93 | 2.29 | 1.74 | 2.12 | 21,335,523 | |
| 04/29/2024 | 1.32 | 1.45 | 1.30 | 1.36 | 1,478,357 | |
| 04/26/2024 | 1.55 | 1.56 | 1.46 | 1.51 | 181,642 | |
| 04/25/2024 | 1.78 | 1.99 | 1.41 | 1.60 | 3,488,208 | |
| 04/24/2024 | 1.86 | 2.35 | 1.85 | 2.30 | 536,186 | |
| 04/23/2024 | 1.71 | 1.85 | 1.68 | 1.79 | 28,374 | |
| 04/22/2024 | 1.80 | 1.93 | 1.73 | 1.75 | 25,527 | |
| 04/19/2024 | 1.89 | 1.95 | 1.77 | 1.78 | 10,326 | |
| 04/18/2024 | 1.91 | 1.96 | 1.81 | 1.85 | 37,911 | |
| 04/17/2024 | 1.67 | 2.09 | 1.67 | 1.96 | 115,080 | |
| 04/16/2024 | 1.52 | 1.72 | 1.52 | 1.67 | 48,891 | |
| 04/15/2024 | 1.76 | 1.84 | 1.57 | 1.57 | 38,778 | |
| 04/12/2024 | 1.91 | 1.91 | 1.76 | 1.76 | 29,512 | |
| 04/11/2024 | 2.00 | 2.05 | 1.91 | 1.94 | 24,158 | |
| 04/10/2024 | 2.09 | 2.11 | 1.95 | 2.05 | 38,282 | |
| 04/09/2024 | 2.07 | 2.13 | 2.07 | 2.11 | 5,730 | |
| 04/08/2024 | 2.05 | 2.14 | 2.05 | 2.11 | 24,922 | |
| 04/05/2024 | 2.21 | 2.21 | 2.03 | 2.10 | 17,941 | |
| 04/04/2024 | 2.13 | 2.19 | 2.12 | 2.19 | 3,795 | |
| 04/03/2024 | 2.15 | 2.22 | 2.07 | 2.19 | 21,579 | |
| 04/02/2024 | 2.00 | 2.15 | 2.00 | 2.12 | 20,139 | |
| 04/01/2024 | 2.20 | 2.23 | 2.01 | 2.05 | 22,065 | |
| 03/28/2024 | 1.99 | 2.14 | 1.99 | 2.11 | 46,138 | |
| 03/27/2024 | 2.09 | 2.09 | 1.94 | 1.96 | 14,688 | |
| 03/26/2024 | 2.11 | 2.18 | 1.82 | 1.92 | 107,917 | |
| 03/25/2024 | 2.14 | 2.22 | 2.06 | 2.14 | 58,529 | |
| 03/22/2024 | 2.09 | 2.23 | 2.07 | 2.19 | 36,905 | |
| 03/21/2024 | 2.27 | 2.30 | 2.08 | 2.18 | 20,093 | |
| 03/20/2024 | 2.31 | 2.31 | 2.16 | 2.25 | 49,199 | |
| 03/19/2024 | 2.54 | 2.54 | 2.33 | 2.35 | 39,514 | |
| 03/18/2024 | 2.49 | 2.59 | 2.40 | 2.51 | 19,514 | |
| 03/15/2024 | 2.51 | 2.58 | 2.37 | 2.43 | 25,556 | |
| 03/14/2024 | 2.54 | 2.61 | 2.46 | 2.50 | 12,976 | |
| 03/13/2024 | 2.47 | 2.68 | 2.47 | 2.59 | 16,190 | |
| 03/12/2024 | 2.48 | 2.59 | 2.47 | 2.48 | 15,437 | |
| 03/11/2024 | 2.70 | 2.73 | 2.50 | 2.52 | 33,963 |
About Cyclacel Pharmaceuticals Stock history
Cyclacel Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Cyclacel is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Cyclacel Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Cyclacel Pharmaceuticals stock prices may prove useful in developing a viable investing in Cyclacel Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 850.8 K | 893.4 K | |
| Net Loss | -24.6 M | -25.8 M |
Cyclacel Pharmaceuticals Stock Technical Analysis
Cyclacel Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Cyclacel Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Cyclacel Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Cyclacel Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Cyclacel to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0237 | |||
| Jensen Alpha | 0.2802 | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | 0.0276 | |||
| Treynor Ratio | (0.23) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |